Effect of large artery atherosclerosis subtype on the efficacy of Ginkgo Diterpene Lactone Meglumine in acute ischemic stroke
10.3969/j.issn.1006-7795.2025.02.008
- VernacularTitle:银杏二萜内酯葡胺注射液对有无大动脉粥样硬化型急性缺血性脑卒中患者的有效性研究
- Author:
Jiao JING
1
;
Siyao ZHANG
1
;
Yanling LIU
1
;
Fen WANG
1
;
Wei XIAO
1
;
Zhenzhong WANG
1
Author Information
1. 中药制药过程控制与智能制造技术全国重点实验室,江苏 连云港 222001
- Publication Type:Journal Article
- Keywords:
large artery atherosclerosis subtypes;
Ginkgo Diterpene Lactone Meglumine injection;
ischemic stroke;
functional outcome;
randomized clinical trial
- From:
Journal of Capital Medical University
2025;46(2):228-233
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of large artery atherosclerosis(LAA)and non-LAA subtypes on the efficacy of Ginkgo Diterpene Lactone Meglumine(GDLM)in patients with acute ischemic stroke.Methods This was a post-hoc analysis of multicenter,randomized,double-blind,placebo-controlled,and parallel-group trial.A total of 3 448 patients who had acute ischemic stroke were randomly assigned in a 1∶1 ratio to receive the injection of GDLM or the placebo once day within 48 h after symptoms and continued for 14 d.The primary outcome was the proportion of patients with a modified Rankin Scale(mRS)of 0 or 1 on day 90 after randomization.Results A total of 3 448 patients were enrolled,with 1 604(46.52% )patients with non-LAA and 1 844(53.48% )with LAA.Compared to the placebo treatment.GDLM injection effectively improve the functional prognosis,with a higher proportion of mRS score of 0-1 in both non-LAA(OR=1.24,95% CI:1.02-1.51;P=0.03)and LAA(OR=1.37,95% CI:1.14-1.65;P<0.001)group.There was no significant interaction between LAA subtypes with treatment(P=0.48 for interaction).Conclusion Among patients with acute ischemic stroke in this randomized clinical trial,GDLM might improve the favorable clinical outcomes at 90 d compared with placebo,regardless of LAA subtypes.Nevertheless,it is necessary to confirm the findings in the future.
